Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening
Journal of Medicinal Chemistry · 09.02.2023 · 66 (3) · 2143-2160
DOI: 10.1021/acs.jmedchem.2c01886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.01.2023. Verfasst von Ram K Modukuri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas77030, United States. Hauptthemen laut MEDLINE: Signal Transduction, DNA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, NCI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
The discovery of monokinase-selective inhibitors for patients is challenging because the 500+ kinases encoded by the human genome share highly conserved catalytic domains. Until now, no selective inhibitors unique for a single transforming growth factor β (TGFβ) family transmembrane receptor kinase, including bone morphogenetic protein receptor type 2 (BMPR2), have been reported. This dearth of receptor-specific kinase inhibitors hinders therapeutic options for skeletal defects and cancer as a result of an overactivated BMP signaling pathway. By screening 4.17 billion "unbiased" and "kinase-biased" DNA-encoded chemical library molecules, we identified hits CDD-1115 and CDD-1431, respectively, that were low-nanomolar selective kinase inhibitors of BMPR2. Structure-activity relationship studies addressed metabolic lability and high-molecular-weight issues, resulting in potent and BMPR2-selective inhibitor analogs CDD-1281 (IC50 = 1.2 nM) and CDD-1653 (IC50 = 2.8 nM), respectively. Our work demonstrates that DNA-encoded chemistry technology (DEC-Tec) is reliable for identifying novel first-in-class, highly potent, and selective kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas77030, United States.
- Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas77030, United States.
ORCID-Profile: Ram K Modukuri, Martin M Matzuk
Förderung
- NICHD NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- Cancer Prevention and Research Institute of Texas
- U.S. Department of Health and Human Services
Zitieren
APA
Modukuri, R. K., Monsivais, D., Li, F., Palaniappan, M., Bohren, K. M., Tan, Z., Ku, A. F., Wang, Y., Madasu, C., Li, J. Y., Tang, S., Miklossy, G., Palmer, S. S., Young, D. W., & Matzuk, M. M. (2023). Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. Journal of Medicinal Chemistry, 66(3), 2143-2160. https://doi.org/10.1021/acs.jmedchem.2c01886
Vancouver
Modukuri RK, Monsivais D, Li F, Palaniappan M, Bohren KM, Tan Z, et al. Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. Journal of Medicinal Chemistry. 2023;66(3):2143-2160. doi:10.1021/acs.jmedchem.2c01886
BibTeX
@article{Modukuri2023,
author = {Modukuri, Ram K and Monsivais, Diana and Li, Feng and Palaniappan, Murugesan and Bohren, Kurt M and Tan, Zhi and Ku, Angela F and Wang, Yong and Madasu, Chandrashekhar and Li, Jian-Yuan and Tang, Suni and Miklossy, Gabriella and Palmer, Stephen S and Young, Damian W and Matzuk, Martin M},
title = {Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {3},
pages = {2143--2160},
doi = {10.1021/acs.jmedchem.2c01886}
}
EUVIMED